Prevail Innovative Wealth Advisors LLC lifted its position in shares of Chemed Co. (NYSE:CHE - Free Report) by 75.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,723 shares of the company's stock after buying an additional 4,166 shares during the quarter. Chemed comprises 1.5% of Prevail Innovative Wealth Advisors LLC's holdings, making the stock its 16th biggest position. Prevail Innovative Wealth Advisors LLC owned 0.06% of Chemed worth $5,151,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of CHE. UMB Bank n.a. increased its stake in Chemed by 300.0% during the 4th quarter. UMB Bank n.a. now owns 52 shares of the company's stock worth $28,000 after acquiring an additional 39 shares during the period. Atala Financial Inc bought a new position in Chemed in the fourth quarter valued at approximately $29,000. CBIZ Investment Advisory Services LLC raised its position in Chemed by 64.7% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 56 shares of the company's stock valued at $30,000 after purchasing an additional 22 shares in the last quarter. Trust Co. of Vermont bought a new stake in Chemed during the fourth quarter worth $34,000. Finally, Tortoise Investment Management LLC boosted its holdings in shares of Chemed by 77.3% in the 4th quarter. Tortoise Investment Management LLC now owns 78 shares of the company's stock valued at $41,000 after purchasing an additional 34 shares in the last quarter. Institutional investors own 95.85% of the company's stock.
Wall Street Analysts Forecast Growth
CHE has been the subject of several recent analyst reports. StockNews.com upgraded Chemed from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Royal Bank of Canada increased their target price on shares of Chemed from $633.00 to $667.00 and gave the stock an "outperform" rating in a report on Friday, March 14th.
Read Our Latest Stock Analysis on Chemed
Insider Activity
In related news, CEO Kevin J. Mcnamara sold 1,000 shares of Chemed stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $615.33, for a total transaction of $615,330.00. Following the sale, the chief executive officer now directly owns 101,679 shares in the company, valued at $62,566,139.07. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.32% of the company's stock.
Chemed Trading Up 0.7 %
Chemed stock traded up $4.46 during mid-day trading on Thursday, reaching $619.14. The company had a trading volume of 39,831 shares, compared to its average volume of 94,579. The business has a fifty day simple moving average of $577.76 and a 200 day simple moving average of $567.62. The company has a market cap of $9.06 billion, a P/E ratio of 31.29, a P/E/G ratio of 2.15 and a beta of 0.43. Chemed Co. has a fifty-two week low of $512.12 and a fifty-two week high of $639.61.
Chemed Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Monday, February 24th were given a $0.50 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $2.00 annualized dividend and a yield of 0.32%. Chemed's dividend payout ratio is presently 10.05%.
About Chemed
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Featured Stories

Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.